Logo image of APLT

APPLIED THERAPEUTICS INC (APLT) Stock Fundamental Analysis

NASDAQ:APLT - Nasdaq - US03828A1016 - Common Stock - Currency: USD

0.5432  +0.01 (+2.49%)

Premarket: 0.5429 0 (-0.06%)

Fundamental Rating

2

Overall APLT gets a fundamental rating of 2 out of 10. We evaluated APLT against 571 industry peers in the Biotechnology industry. APLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. APLT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APLT has reported negative net income.
In the past year APLT has reported a negative cash flow from operations.
APLT had negative earnings in each of the past 5 years.
In the past 5 years APLT always reported negative operating cash flow.
APLT Yearly Net Income VS EBIT VS OCF VS FCFAPLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of APLT (-252.80%) is worse than 93.05% of its industry peers.
APLT has a worse Return On Equity (-4572.20%) than 85.56% of its industry peers.
Industry RankSector Rank
ROA -252.8%
ROE -4572.2%
ROIC N/A
ROA(3y)-183.57%
ROA(5y)-146.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APLT Yearly ROA, ROE, ROICAPLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K -1.5K -2K

1.3 Margins

APLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APLT Yearly Profit, Operating, Gross MarginsAPLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

APLT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, APLT has more shares outstanding
APLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APLT Yearly Shares OutstandingAPLT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
APLT Yearly Total Debt VS Total AssetsAPLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.79, we must say that APLT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.79, APLT is doing worse than 77.72% of the companies in the same industry.
There is no outstanding debt for APLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.79
ROIC/WACCN/A
WACCN/A
APLT Yearly LT Debt VS Equity VS FCFAPLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

APLT has a Current Ratio of 1.06. This is a normal value and indicates that APLT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of APLT (1.06) is worse than 88.24% of its industry peers.
APLT has a Quick Ratio of 1.06. This is a normal value and indicates that APLT is financially healthy and should not expect problems in meeting its short term obligations.
APLT's Quick ratio of 1.06 is on the low side compared to the rest of the industry. APLT is outperformed by 86.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 1.06
APLT Yearly Current Assets VS Current LiabilitesAPLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for APLT have decreased strongly by -24.58% in the last year.
APLT shows a decrease in Revenue. In the last year, the revenue decreased by -1.98%.
EPS 1Y (TTM)-24.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.13%
Revenue 1Y (TTM)-1.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.16% on average over the next years. This is quite good.
The Revenue is expected to grow by 64.01% on average over the next years. This is a very strong growth
EPS Next Y-9.6%
EPS Next 2Y27.38%
EPS Next 3Y21.96%
EPS Next 5Y12.16%
Revenue Next Year-95%
Revenue Next 2Y16.69%
Revenue Next 3Y82.43%
Revenue Next 5Y64.01%

3.3 Evolution

APLT Yearly Revenue VS EstimatesAPLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
APLT Yearly EPS VS EstimatesAPLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLT Price Earnings VS Forward Price EarningsAPLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLT Per share dataAPLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as APLT's earnings are expected to grow with 21.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.38%
EPS Next 3Y21.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED THERAPEUTICS INC

NASDAQ:APLT (2/24/2025, 8:12:47 PM)

Premarket: 0.5429 0 (-0.06%)

0.5432

+0.01 (+2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-14 2025-03-14/amc
Inst Owners106.55%
Inst Owner Change-94.95%
Ins Owners1.64%
Ins Owner Change5.81%
Market Cap63.21M
Analysts81.67
Price Target4.59 (744.99%)
Short Float %20.72%
Short Ratio3.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.93%
Min EPS beat(2)-197.84%
Max EPS beat(2)111.97%
EPS beat(4)1
Avg EPS beat(4)-110.97%
Min EPS beat(4)-311.83%
Max EPS beat(4)111.97%
EPS beat(8)3
Avg EPS beat(8)-56.25%
EPS beat(12)6
Avg EPS beat(12)-34.77%
EPS beat(16)10
Avg EPS beat(16)-23.46%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-64.84%
EPS NQ rev (1m)-14.29%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-52.94%
Revenue NQ rev (1m)-83.43%
Revenue NQ rev (3m)-83.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-70.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.05
P/FCF N/A
P/OCF N/A
P/B 10.73
P/tB 10.73
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0.09
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -252.8%
ROE -4572.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-183.57%
ROA(5y)-146.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 1.06
Altman-Z -11.79
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.13%
EPS Next Y-9.6%
EPS Next 2Y27.38%
EPS Next 3Y21.96%
EPS Next 5Y12.16%
Revenue 1Y (TTM)-1.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-95%
Revenue Next 2Y16.69%
Revenue Next 3Y82.43%
Revenue Next 5Y64.01%
EBIT growth 1Y-117.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.16%
EBIT Next 3Y38%
EBIT Next 5YN/A
FCF growth 1Y8.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.19%
OCF growth 3YN/A
OCF growth 5YN/A